XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2021 $ 38,000 $ 442,259,000 $ (138,000) $ (347,104,000) $ 95,055,000
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 37,918,395        
Exercises of vested stock options   12,000     12,000
Exercises of vested stock options (in shares) 11,484        
Vesting of restricted stock units (in shares) 312,090        
Stock based compensation expense   2,268,000     2,268,000
Net unrealized (loss) gain on available-for-sale securities     (85,000)   (85,000)
Net income (loss)       (21,319,000) (21,319,000)
Stockholders' Equity, Ending Balance at Mar. 31, 2022 $ 38,000 444,539,000 (223,000) (368,423,000) 75,931,000
Shares, Outstanding, Ending Balance at Mar. 31, 2022 38,241,969        
Stockholders' Equity, Beginning Balance at Dec. 31, 2021 $ 38,000 442,259,000 (138,000) (347,104,000) 95,055,000
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 37,918,395        
Net unrealized (loss) gain on available-for-sale securities         (226,000)
Net income (loss)         (40,406,000)
Stockholders' Equity, Ending Balance at Jun. 30, 2022 $ 38,000 447,888,000 (364,000) (387,510,000) 60,052,000
Shares, Outstanding, Ending Balance at Jun. 30, 2022 38,439,251        
Stockholders' Equity, Beginning Balance at Mar. 31, 2022 $ 38,000 444,539,000 (223,000) (368,423,000) 75,931,000
Shares, Outstanding, Beginning Balance at Mar. 31, 2022 38,241,969        
Exercises of vested stock options   575,000     575,000
Exercises of vested stock options (in shares) 63,012        
Vesting of restricted stock units (in shares) 32,165        
Issuance of common stock under ESPP   313,000     313,000
Issuance of common stock under ESPP (in shares) 102,105        
Stock based compensation expense   2,460,000     2,460,000
Net unrealized (loss) gain on available-for-sale securities     (141,000)   (141,000)
Net income (loss)       (19,087,000) (19,087,000)
Stockholders' Equity, Ending Balance at Jun. 30, 2022 $ 38,000 447,888,000 (364,000) (387,510,000) 60,052,000
Shares, Outstanding, Ending Balance at Jun. 30, 2022 38,439,251        
Stockholders' Equity, Beginning Balance at Dec. 31, 2022 $ 38,000 452,713,000 (219,000) (393,512,000) 59,020,000
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 38,613,891        
Exercises of vested stock options   185,000     185,000
Exercises of vested stock options (in shares) 51,993        
Vesting of restricted stock units (in shares) 374,417        
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement $ 5,000 31,116,000     31,121,000
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement (in shares) 4,395,588        
Stock based compensation expense   2,504,000     2,504,000
Net unrealized (loss) gain on available-for-sale securities     87,000   87,000
Net income (loss)       124,044,000 124,044,000
Stockholders' Equity, Ending Balance at Mar. 31, 2023 $ 43,000 486,518,000 (132,000) (269,468,000) 216,961,000
Shares, Outstanding, Ending Balance at Mar. 31, 2023 43,435,889        
Stockholders' Equity, Beginning Balance at Dec. 31, 2022 $ 38,000 452,713,000 (219,000) (393,512,000) $ 59,020,000
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 38,613,891        
Exercises of vested stock options (in shares)         250,341
Net unrealized (loss) gain on available-for-sale securities         $ 86,000
Net income (loss)         101,836,000
Stockholders' Equity, Ending Balance at Jun. 30, 2023 $ 44,000 490,791,000 (133,000) (291,676,000) 199,026,000
Shares, Outstanding, Ending Balance at Jun. 30, 2023 43,759,409        
Stockholders' Equity, Beginning Balance at Mar. 31, 2023 $ 43,000 486,518,000 (132,000) (269,468,000) 216,961,000
Shares, Outstanding, Beginning Balance at Mar. 31, 2023 43,435,889        
Exercises of vested stock options $ 1,000 1,228,000     1,229,000
Exercises of vested stock options (in shares) 198,348        
Vesting of restricted stock units (in shares) 62,828        
Issuance of common stock under ESPP $ 62,344 418,000     418,000
Stock based compensation expense   2,627,000     2,627,000
Net unrealized (loss) gain on available-for-sale securities     (1,000)   (1,000)
Net income (loss)       (22,208,000) (22,208,000)
Stockholders' Equity, Ending Balance at Jun. 30, 2023 $ 44,000 $ 490,791,000 $ (133,000) $ (291,676,000) $ 199,026,000
Shares, Outstanding, Ending Balance at Jun. 30, 2023 43,759,409